Related Experiment Video
Updated: May 20, 2025
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Small cell transformation in a patient with BRAF V600E-mutated advanced non-small cell lung cancer
Thanakorn Charoenthanadhol1, Nipon Chaisuriya2, Siraphong Putraveephong3
1Internal Medicine, Khon Kaen University Faculty of Medicine, Khon Kaen, Khon Kaen, Thailand.
Abstract:
Non-small cell lung cancer (NSCLC) with a BRAF V600E mutation is rare and associated with a worse prognosis compared with wild-type BRAF. The first-line treatment options include a combination of a BRAF inhibitor and a MEK inhibitor or immunotherapy with or without chemotherapy. Unlike advanced NSCLC with common EGFR mutations or ALK rearrangements, the mechanisms of resistance are poorly understood. We report a case of small cell transformation after treatment with a BRAF inhibitor and a MEK inhibitor, which illustrates one potential resistance mechanism. We extrapolated therapeutic data from de novo small cell lung cancer to this case. However, the outcome was unsatisfactory.
Insights
BRAF V600E mutated non-small cell lung cancer (NSCLC) rarely transforms to small cell lung cancer after targeted therapy. This case highlights a potential resistance mechanism, but treatment outcomes remain poor.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) with BRAF V600E mutations presents a unique clinical challenge with a poorer prognosis.
- Standard first-line treatments include BRAF/MEK inhibitors or immunotherapy, but resistance mechanisms are not well-defined.
- Understanding resistance is crucial for improving patient outcomes in this rare NSCLC subtype.
Purpose of the Study:
- To report a case of small cell transformation in BRAF V600E-mutated NSCLC after BRAF/MEK inhibitor treatment.
- To explore small cell transformation as a potential mechanism of therapeutic resistance.
- To evaluate the efficacy of extrapolated treatment strategies for this rare transformation.
Main Methods:
- Case report of a patient with BRAF V600E-mutated NSCLC.
- Treatment with a BRAF inhibitor and a MEK inhibitor.
- Observation of small cell transformation.
- Application of therapeutic data from de novo small cell lung cancer.
Main Results:
- The patient developed small cell lung cancer transformation after BRAF/MEK inhibitor therapy.
- Extrapolated treatment strategies based on de novo small cell lung cancer yielded unsatisfactory outcomes.
- This transformation represents a potential mechanism of acquired resistance to targeted therapy.
Conclusions:
- Small cell transformation can occur in BRAF V600E-mutated NSCLC as a resistance mechanism to BRAF/MEK inhibitors.
- Current treatment approaches for this transformation are inadequate.
- Further research is needed to understand and overcome resistance in this specific NSCLC subset.
